Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002306 · ClinicalTrials.gov registry record · NA

A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B

A NA study of HIV Infections and Meningitis, Cryptococcal, sponsored by Pfizer.

Completed
Registry status
NA
Development phase
14
Study locations

NCT00002306: Completed NA study of HIV Infections and Meningitis, Cryptococcal, sponsored by Pfizer.

NCT00002306 is a NA study of HIV Infections and Meningitis, Cryptococcal that has completed, run by Pfizer. The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002306, a NA study of HIV Infections and Meningitis, Cryptococcal, has completed, sponsored by Pfizer.

COMPLETED
Registry status
NA
Development phase
14
Study locations

Study Summary

To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in patients who have had an unsatisfactory response to or have experienced unacceptable toxicity with amphotericin B.

Interventions

  • DRUG Fluconazole

Study Locations (14)

Texas

  • United States Air Force Med Ctr - Lackland Air Force Base
  • Southwest Texas Methodist Hosp - San Antonio
  • Univ TX San Antonio Health Science Ctr - San Antonio

Georgia

  • Emory Univ School of Medicine - Atlanta
  • Med College of Georgia - Augusta

New York

  • Saint Luke's - Roosevelt Hosp Ctr - New York
  • Bronx Veterans Administration / Mount Sinai Hosp - The Bronx

Alabama

  • Univ of Alabama at Birmingham - Birmingham

District of Columbia

  • George Washington Univ Med Ctr - Washington D.C.

Florida

  • Univ of South Florida - Tampa

Massachusetts

  • Univ Hosp - Boston

Michigan

  • Ann Arbor Veterans Administration Med Ctr - Ann Arbor

Trial Details

FieldValue
Phase NA
Pfizer

1,845 total trials

What the finished NCT00002306 record still lists

NCT00002306 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Fluconazole is the first listed.

NCT00002306 lists 14 locations in 10 states (Texas, Georgia, New York).

Frequently Asked Questions

What is clinical trial NCT00002306 about?

NCT00002306 is a clinical study titled "A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B". To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in patients who have had an unsatisfactory response to or have experienced unacceptable toxicity with amphotericin B.

What is the current status of trial NCT00002306?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002306 study?

This clinical trial studies the following conditions: HIV Infections, Meningitis, Cryptococcal.

What interventions are being tested in trial NCT00002306?

The interventions under investigation include: Fluconazole (DRUG).

Who is sponsoring clinical trial NCT00002306?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002306 being conducted?

This trial has 14 study locations across Alabama, District of Columbia, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Source: ClinicalTrials.gov NCT00002306, the US trial registry maintained by the National Library of Medicine. NCT00002306 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.